



PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 63419

Title: Successful treatment of refractory lung adenocarcinoma harboring a germline BRC mutation with olaparib: A case report

Reviewer's code: 05187436

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Italy

Author's Country/Territory: China

Manuscript submission date: 2021-02-02

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-04-28 17:16

Reviewer performed review: 2021-04-28 17:21

Review time: 1 Hour

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent [] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) [] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	<input checked="" type="checkbox"/> Yes [] No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous [] Onymous Conflicts-of-Interest: [] Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Authors report a case of a 62 year old patient with a refractory lung adenocarcinoma harboring a germline BRCA2 mutation who responded successfully to treatment with olaparib. In my opinion the case is very interesting and very well studied. The way authors followed the case clinically and scientifically is excellent. Therefore the paper can be accepted in the present form.